Selected research
Market Structure
Global Blood-derived Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Blood-derived Products market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Blood-derived Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Blood-derived Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Blood-derived Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Blood-derived Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Blood-derived Products include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, Shuanglin Bio, Shanghai RAAS, Hualan Bio, Boya Bio and CBPO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Blood-derived Products market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Blood-derived Products and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Blood-derived Products sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Blood-derived Products market size, projected growth trends, production technologies, key applications, and end-use industries.
Blood-derived Products Segment by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
Shuanglin Bio
Shanghai RAAS
Hualan Bio
Boya Bio
CBPO
Octapharma
LFB Group
Kedrion
Grifols
CSL
Blood-derived Products Segment by Type
Coagulation Factors
Immunoglobulins
Albumin
Others
Blood-derived Products Segment by Application
Therapeutics
Excipient
Other
Blood-derived Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood-derived Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood-derived Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood-derived Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Blood-derived Products market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood-derived Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Blood-derived Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Blood-derived Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Coagulation Factors
- Immunoglobulins
- Albumin
- Others
Applications
- Therapeutics
- Excipient
- Other
Companies covered
- Yuanda Shuyang
- Takeda
- Weiguang Bio
- Tiantan Bio
- Shuanglin Bio
- Shanghai RAAS
- Hualan Bio
- Boya Bio
- CBPO
- Octapharma
- LFB Group
- Kedrion
- Grifols
- CSL
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Blood-derived Products Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Blood-derived Products Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Blood-derived Products Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Blood-derived Products Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Blood-derived Products Market Dynamics
- 2.1 Blood-derived Products Industry Trends
- 2.2 Blood-derived Products Industry Drivers
- 2.3 Blood-derived Products Industry Opportunities and Challenges
- 2.4 Blood-derived Products Industry Restraints
3 Blood-derived Products Market by Manufacturers
- 3.1 Global Blood-derived Products Revenue by Manufacturers (2021-2026)
- 3.2 Global Blood-derived Products Sales by Manufacturers (2021-2026)
- 3.3 Global Blood-derived Products Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Blood-derived Products Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Blood-derived Products Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Blood-derived Products Manufacturers, Product Type & Application
- 3.7 Global Blood-derived Products Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Blood-derived Products Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Blood-derived Products Players Market Share by Revenue in 2025
- 3.8.3 2025 Blood-derived Products Tier 1, Tier 2, and Tier 3
4 Blood-derived Products Market by Type
- 4.1 Blood-derived Products Type Introduction
- 4.1.1 Coagulation Factors
- 4.1.2 Immunoglobulins
- 4.1.3 Albumin
- 4.1.4 Others
- 4.2 Global Blood-derived Products Sales by Type
- 4.2.1 Global Blood-derived Products Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Blood-derived Products Sales by Type (2021-2032)
- 4.2.3 Global Blood-derived Products Sales Market Share by Type (2021-2032)
- 4.3 Global Blood-derived Products Revenue by Type
- 4.3.1 Global Blood-derived Products Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Blood-derived Products Revenue by Type (2021-2032)
- 4.3.3 Global Blood-derived Products Revenue Market Share by Type (2021-2032)
5 Blood-derived Products Market by Application
- 5.1 Blood-derived Products Application Introduction
- 5.1.1 Therapeutics
- 5.1.2 Excipient
- 5.1.3 Other
- 5.2 Global Blood-derived Products Sales by Application
- 5.2.1 Global Blood-derived Products Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Blood-derived Products Sales by Application (2021-2032)
- 5.2.3 Global Blood-derived Products Sales Market Share by Application (2021-2032)
- 5.3 Global Blood-derived Products Revenue by Application
- 5.3.1 Global Blood-derived Products Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Blood-derived Products Revenue by Application (2021-2032)
- 5.3.3 Global Blood-derived Products Revenue Market Share by Application (2021-2032)
6 Global Blood-derived Products Sales by Region
- 6.1 Global Blood-derived Products Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Blood-derived Products Sales by Region (2021-2032)
- 6.2.1 Global Blood-derived Products Sales by Region (2021-2026)
- 6.2.2 Global Blood-derived Products Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Blood-derived Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Blood-derived Products Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Blood-derived Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Blood-derived Products Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Blood-derived Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Blood-derived Products Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Blood-derived Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Blood-derived Products Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Blood-derived Products Revenue by Region
- 7.1 Global Blood-derived Products Revenue by Region
- 7.1.1 Global Blood-derived Products Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Blood-derived Products Revenue by Region (2021-2026)
- 7.1.3 Global Blood-derived Products Revenue by Region (2027-2032)
- 7.1.4 Global Blood-derived Products Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Blood-derived Products Revenue (2021-2032)
- 7.2.2 North America Blood-derived Products Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Blood-derived Products Revenue (2021-2032)
- 7.3.2 Europe Blood-derived Products Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Blood-derived Products Revenue (2021-2032)
- 7.4.2 Asia-Pacific Blood-derived Products Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Blood-derived Products Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Blood-derived Products Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Yuanda Shuyang
- 8.1.1 Yuanda Shuyang Company Information
- 8.1.2 Yuanda Shuyang Business Overview
- 8.1.3 Yuanda Shuyang Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Yuanda Shuyang Blood-derived Products Product Portfolio
- 8.1.5 Yuanda Shuyang Recent Developments
- 8.2 Takeda
- 8.2.1 Takeda Company Information
- 8.2.2 Takeda Business Overview
- 8.2.3 Takeda Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Takeda Blood-derived Products Product Portfolio
- 8.2.5 Takeda Recent Developments
- 8.3 Weiguang Bio
- 8.3.1 Weiguang Bio Company Information
- 8.3.2 Weiguang Bio Business Overview
- 8.3.3 Weiguang Bio Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Weiguang Bio Blood-derived Products Product Portfolio
- 8.3.5 Weiguang Bio Recent Developments
- 8.4 Tiantan Bio
- 8.4.1 Tiantan Bio Company Information
- 8.4.2 Tiantan Bio Business Overview
- 8.4.3 Tiantan Bio Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Tiantan Bio Blood-derived Products Product Portfolio
- 8.4.5 Tiantan Bio Recent Developments
- 8.5 Shuanglin Bio
- 8.5.1 Shuanglin Bio Company Information
- 8.5.2 Shuanglin Bio Business Overview
- 8.5.3 Shuanglin Bio Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Shuanglin Bio Blood-derived Products Product Portfolio
- 8.5.5 Shuanglin Bio Recent Developments
- 8.6 Shanghai RAAS
- 8.6.1 Shanghai RAAS Company Information
- 8.6.2 Shanghai RAAS Business Overview
- 8.6.3 Shanghai RAAS Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Shanghai RAAS Blood-derived Products Product Portfolio
- 8.6.5 Shanghai RAAS Recent Developments
- 8.7 Hualan Bio
- 8.7.1 Hualan Bio Company Information
- 8.7.2 Hualan Bio Business Overview
- 8.7.3 Hualan Bio Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Hualan Bio Blood-derived Products Product Portfolio
- 8.7.5 Hualan Bio Recent Developments
- 8.8 Boya Bio
- 8.8.1 Boya Bio Company Information
- 8.8.2 Boya Bio Business Overview
- 8.8.3 Boya Bio Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Boya Bio Blood-derived Products Product Portfolio
- 8.8.5 Boya Bio Recent Developments
- 8.9 CBPO
- 8.9.1 CBPO Company Information
- 8.9.2 CBPO Business Overview
- 8.9.3 CBPO Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 CBPO Blood-derived Products Product Portfolio
- 8.9.5 CBPO Recent Developments
- 8.10 Octapharma
- 8.10.1 Octapharma Company Information
- 8.10.2 Octapharma Business Overview
- 8.10.3 Octapharma Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Octapharma Blood-derived Products Product Portfolio
- 8.10.5 Octapharma Recent Developments
- 8.11 LFB Group
- 8.11.1 LFB Group Company Information
- 8.11.2 LFB Group Business Overview
- 8.11.3 LFB Group Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 LFB Group Blood-derived Products Product Portfolio
- 8.11.5 LFB Group Recent Developments
- 8.12 Kedrion
- 8.12.1 Kedrion Company Information
- 8.12.2 Kedrion Business Overview
- 8.12.3 Kedrion Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Kedrion Blood-derived Products Product Portfolio
- 8.12.5 Kedrion Recent Developments
- 8.13 Grifols
- 8.13.1 Grifols Company Information
- 8.13.2 Grifols Business Overview
- 8.13.3 Grifols Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Grifols Blood-derived Products Product Portfolio
- 8.13.5 Grifols Recent Developments
- 8.14 CSL
- 8.14.1 CSL Company Information
- 8.14.2 CSL Business Overview
- 8.14.3 CSL Blood-derived Products Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 CSL Blood-derived Products Product Portfolio
- 8.14.5 CSL Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Blood-derived Products Value Chain Analysis
- 9.1.1 Blood-derived Products Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Blood-derived Products Production Mode & Process
- 9.2 Blood-derived Products Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Blood-derived Products Distributors
- 9.2.3 Blood-derived Products Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst